Carine Tang

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.

D. White, T. Hughes, Amy Hughes, 2017, Blood.

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways

D. White, T. Hughes, S. Moore, 2011, Leukemia & lymphoma.

TKI resistance in CML cell lines : investigating resistance pathways.

Carine Tang, 2012 .

KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.

Deborah L White, Susan Branford, D. White, 2015, Blood.

Chronic Myeloid Leukemia Patients with Deep Molecular Responses to Tyrosine Kinase Inhibitors Have Increased Effector Natural Killer and Cytotoxic T Cell Immune Responses to Leukaemia-Associated Antigens and Concomitant Reduced Immune Suppressors

T. Hughes, Amy Hughes, A. Yong, 2015 .

CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.

Amy Hughes, A. Yong, Carine Tang, 2017, Blood.